FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166366899> ?p ?o ?g. }

• W2166366899 endingPage "3391" @default.
• W2166366899 startingPage "3380" @default.
• W2166366899 abstract "Subtype-selective antagonists of the peripheral-type (CCK-A) and the central-type (CCK-B) cholecystokinin (CCK) receptors were employed to determine the receptor subtype(s) mediating the modulatory actions of CCK on dopamine-induced changes in exploratory activity at three sites in the mesolimbic pathway of the rat. The CCK-A antagonist L-364,718 (10 ng) blocked CCK potentiation of dopamine-induced hyperlocomotion in the medial posterior nucleus accumbens. The CCK-B antagonist CI-988 (20 ng) blocked CCK inhibition of dopamine-induced hyperlocomotion in the anterior nucleus accumbens. The CCK-B antagonists CI-988 (20 ng) and L- 365,260 (10 ng) blocked CCK potentiation of dopamine-induced hypolocomotion in the ventral tegmental area. These data indicate a CCK- B pharmacology in the cell body and anterior terminal field, and a CCK- A pharmacology in the posterior terminal field, of the mesolimbic dopamine pathway. Behavioral analyses using the selective CCK antagonists did not detect a contribution of endogenous CCK to exploratory locomotion. L-364,718 (10 ng), L-365,260 (10 ng), and CI- 988 (20 ng or 2 micrograms), microinjected into the medial posterior nucleus accumbens, anterior nucleus accumbens, or ventral tegmental area, had no effect on baseline exploratory locomotion or on dopamine- induced changes in exploratory locomotion. Using a dark-induced hyperlocomotion paradigm, the CCK antagonists at these doses at these sites and intraperitoneally had no effect on the high levels of exploratory locomotor activity exhibited by the rats in the dark testing environment, or the lower levels of exploratory activity in the lighted environment. Endogenous CCK may not be released during dopamine- induced hyperlocomotion or dark-induced hyperlocomotion, or endogenous CCK may not contribute significantly to exploratory behaviors mediated through the mesolimbic dopamine pathway. Utilization of these potent, selective, nonpeptide CCK antagonists, with the doses, vehicles, and routes of administration developed in the present studies, will guide further investigations into the role of endogenous CCK in other facets of mesolimbic function." @default.
• W2166366899 created "2016-06-24" @default.
• W2166366899 creator A5063501456 @default.
• W2166366899 date "1992-09-01" @default.
• W2166366899 modified "2023-09-28" @default.
• W2166366899 title "Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway" @default.
• W2166366899 cites W1529961551 @default.
• W2166366899 cites W1592010340 @default.
• W2166366899 cites W1596805218 @default.
• W2166366899 cites W1873255488 @default.
• W2166366899 cites W1977141794 @default.
• W2166366899 cites W1977398250 @default.
• W2166366899 cites W1982228241 @default.
• W2166366899 cites W1986832734 @default.
• W2166366899 cites W1991316248 @default.
• W2166366899 cites W1991379023 @default.
• W2166366899 cites W1991714764 @default.
• W2166366899 cites W1995201487 @default.
• W2166366899 cites W2000394693 @default.
• W2166366899 cites W2001220158 @default.
• W2166366899 cites W2002134809 @default.
• W2166366899 cites W2015710803 @default.
• W2166366899 cites W2018510172 @default.
• W2166366899 cites W2021975014 @default.
• W2166366899 cites W2022541536 @default.
• W2166366899 cites W2023724563 @default.
• W2166366899 cites W2024511383 @default.
• W2166366899 cites W2027119507 @default.
• W2166366899 cites W2028097093 @default.
• W2166366899 cites W2032040549 @default.
• W2166366899 cites W2032511112 @default.
• W2166366899 cites W2039811484 @default.
• W2166366899 cites W2042554229 @default.
• W2166366899 cites W2045166398 @default.
• W2166366899 cites W2046604017 @default.
• W2166366899 cites W2047488955 @default.
• W2166366899 cites W2049758555 @default.
• W2166366899 cites W2050760271 @default.
• W2166366899 cites W2054611691 @default.
• W2166366899 cites W2062528031 @default.
• W2166366899 cites W2063238667 @default.
• W2166366899 cites W2066334928 @default.
• W2166366899 cites W2069717883 @default.
• W2166366899 cites W2071231226 @default.
• W2166366899 cites W2073414935 @default.
• W2166366899 cites W2073595900 @default.
• W2166366899 cites W2074128077 @default.
• W2166366899 cites W2075776256 @default.
• W2166366899 cites W2078111444 @default.
• W2166366899 cites W2080101710 @default.
• W2166366899 cites W2083854182 @default.
• W2166366899 cites W2085917181 @default.
• W2166366899 cites W2088750285 @default.
• W2166366899 cites W2093466245 @default.
• W2166366899 cites W2163815564 @default.
• W2166366899 cites W2262015248 @default.
• W2166366899 cites W2461723826 @default.
• W2166366899 cites W2150325253 @default.
• W2166366899 doi "https://doi.org/10.1523/jneurosci.12-09-03380.1992" @default.
• W2166366899 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6575738" @default.
• W2166366899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1527584" @default.
• W2166366899 hasPublicationYear "1992" @default.
• W2166366899 type Work @default.
• W2166366899 sameAs 2166366899 @default.
• W2166366899 citedByCount "92" @default.
• W2166366899 countsByYear W21663668992012 @default.
• W2166366899 countsByYear W21663668992013 @default.
• W2166366899 countsByYear W21663668992014 @default.
• W2166366899 countsByYear W21663668992017 @default.
• W2166366899 countsByYear W21663668992018 @default.
• W2166366899 countsByYear W21663668992022 @default.
• W2166366899 crossrefType "journal-article" @default.
• W2166366899 hasAuthorship W2166366899A5063501456 @default.
• W2166366899 hasBestOaLocation W21663668992 @default.
• W2166366899 hasConcept C107539642 @default.
• W2166366899 hasConcept C120069818 @default.
• W2166366899 hasConcept C126322002 @default.
• W2166366899 hasConcept C134018914 @default.
• W2166366899 hasConcept C137183658 @default.
• W2166366899 hasConcept C169760540 @default.
• W2166366899 hasConcept C170493617 @default.
• W2166366899 hasConcept C185592680 @default.
• W2166366899 hasConcept C25274449 @default.
• W2166366899 hasConcept C2776552330 @default.
• W2166366899 hasConcept C2776885963 @default.
• W2166366899 hasConcept C2777593968 @default.
• W2166366899 hasConcept C2780948874 @default.
• W2166366899 hasConcept C32110497 @default.
• W2166366899 hasConcept C513476851 @default.
• W2166366899 hasConcept C71924100 @default.
• W2166366899 hasConcept C86803240 @default.
• W2166366899 hasConcept C98274493 @default.
• W2166366899 hasConceptScore W2166366899C107539642 @default.
• W2166366899 hasConceptScore W2166366899C120069818 @default.
• W2166366899 hasConceptScore W2166366899C126322002 @default.
• W2166366899 hasConceptScore W2166366899C134018914 @default.
• W2166366899 hasConceptScore W2166366899C137183658 @default.
• W2166366899 hasConceptScore W2166366899C169760540 @default.

• next